A1-antitrypsin (AT) deficiency (ATD) is the most common genetic cause of liver disease. The classical form of ATD is due to a single missense mutation (Z) that causes the mutant protein (ATZ) to misfold and accumulate within the endoplasmic reticulum (ER) of liver cells as toxic oligomers, polymers or aggregates. However, due to genetic and environmental modifiers, there is marked variation in the incidence and severity of liver disease among homozygotes. Since the only treatment for severe ATZ-induced hepatic injury is liver transplantation, the development of an animal model amenable to pre-clinical, high-throughput drug screening technologies would greatly assist in the discovery of new compounds that reduce or eliminate ATZ-induced hepatotoxicity. The value of the model would be markedly increased if it also possessed genetic tractability to: 1) elucidate the genetic modifiers of both tissue damage and the endogenous proteostasis pathways that protect against protein misfolding-induced injury, and 2) pinpoint which biochemical pathways and/or molecules are targeted by newly discovered compounds. We show that ATZ induced liver disease is modeled accurately in the nematode, C. elegans. Transgenic animals expressing wild-type human AT secreted the protein. In contrast, animals expressing ATZ faithfully recapitulated the ER trafficking defect of ATZ by demonstrating intracellular inclusions (dilated ER cisterna), and becoming unhealthy as shown by slow growth, small brood sizes and decreased longevity. Using this model we developed an automated, live-animal, high-content screening (HOS) assay that rivals that of any cell-based system. We validated this system by discovering -30 hit compounds, including several that reduced ATZ accumulation by enhancing autophagy, a known pathway of ATZ elimination. Using a modification of our HOS strategy, we also developed a semi-automated technology that reduces the labor intensiveness of genome-wide RNAi screens. We identified several potential genetic modifiers/pathways of ATZ accumulation. Taken together, these studies demonstrated that this transgenic C. elegans model is a powerful platform to initiate the discovery of both novel drugs and genes that modify ATZ hepatotoxicity.
The aims of Project 2 are to discover additional hit compounds for the treatment of ATZ-induced disease phenotypes in C. elegans by both HCS and computer-aided molecular modeling, identify disease modifiers of major and minor effect, and to determine whether different mutant disease modifiers alter responsiveness to therapeutic compounds.

Public Health Relevance

Alpha-1-antitrypsin deficiency is a leading genetic cause of liver injury, but lacks effective treatments. The goal of this study is to model this disease in a simple organism, and use this tool to screen a large collection of chemical compounds for novel drugs that block the development of liver injury.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK096990-02
Application #
8548329
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2013
Total Cost
$345,764
Indirect Cost
$109,036
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Paranjpe, Shirish; Bowen, William C; Mars, Wendy M et al. (2016) Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation. Hepatology 64:1711-1724
Khan, Zahida; Yokota, Shinichiro; Ono, Yoshihiro et al. (2016) BILE DUCT LIGATION INDUCES ATZ GLOBULE CLEARANCE IN A MOUSE MODEL OF ALPHA-1 ANTITRYPSIN DEFICIENCY. Gene Expr :
Stern, Andrew M; Schurdak, Mark E; Bahar, Ivet et al. (2016) A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. J Biomol Screen 21:521-34
Shi, Shujie; Luke, Cliff J; Miedel, Mark T et al. (2016) Activation of the Caenorhabditis elegans Degenerin Channel by Shear Stress Requires the MEC-10 Subunit. J Biol Chem 291:14012-22
Khan, Zahida; Orr, Anne V; Michalopoulos, George K et al. (2016) IMMUNOHISTOCHEMICAL ANALYSIS OF THE STEM CELL MARKER LGR5 IN PEDIATRIC LIVER DISEASE. Pediatr Dev Pathol :
Khan, Zahida; Yokota, Shinichiro; Ono, Yoshihiro et al. (2016) BILE DUCT LIGATION INDUCES ATZ GLOBULE CLEARANCE IN A MOUSE MODEL OF ALPHA-1 ANTITRYPSIN DEFICIENCY. Gene Expr :
Khan, Zahida; Venkat, Veena L; Soltys, Kyle A et al. (2016) A CHALLENGING CASE OF SEVERE INFANTILE CHOLESTASIS IN ALPHA-1 ANTITRYPSIN DEFICIENCY. Pediatr Dev Pathol :
Roy-Chowdhury, Jayanta; Schilsky, Michael L (2016) Gene therapy of Wilson disease: A "golden" opportunity using rAAV on the 50th anniversary of the discovery of the virus. J Hepatol 64:265-7
Luke, Cliff J; O'Reilly, Linda P (2015) Microscopic Investigation of Protein Function in C. elegans Using Fluorescent Imaging. Curr Protoc Cytom 74:12.41.1-17
Hidvegi, Tunda; Stolz, Donna B; Alcorn, John F et al. (2015) Enhancing Autophagy with Drugs or Lung-directed Gene Therapy Reverses the Pathological Effects of Respiratory Epithelial Cell Proteinopathy. J Biol Chem 290:29742-57

Showing the most recent 10 out of 32 publications